Boston Trust Walden Corp boosted its holdings in Chemed Co. (NYSE:CHE - Free Report) by 10.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 242,172 shares of the company's stock after acquiring an additional 22,105 shares during the quarter. Chemed comprises about 0.9% of Boston Trust Walden Corp's investment portfolio, making the stock its 20th biggest holding. Boston Trust Walden Corp owned 1.61% of Chemed worth $128,303,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. UMB Bank n.a. raised its position in Chemed by 300.0% in the fourth quarter. UMB Bank n.a. now owns 52 shares of the company's stock worth $28,000 after acquiring an additional 39 shares in the last quarter. Trust Co. of Vermont bought a new stake in Chemed in the fourth quarter worth about $34,000. GAMMA Investing LLC increased its stake in Chemed by 60.5% in the 3rd quarter. GAMMA Investing LLC now owns 138 shares of the company's stock worth $83,000 after purchasing an additional 52 shares in the last quarter. Sound Income Strategies LLC purchased a new position in Chemed in the 3rd quarter worth about $201,000. Finally, Farther Finance Advisors LLC increased its stake in Chemed by 2,314.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 338 shares of the company's stock worth $203,000 after purchasing an additional 324 shares in the last quarter. 95.85% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on CHE. Royal Bank of Canada dropped their price target on Chemed from $697.00 to $633.00 and set an "outperform" rating on the stock in a research note on Tuesday, November 5th. StockNews.com raised Chemed from a "hold" rating to a "buy" rating in a research note on Saturday, November 30th.
Check Out Our Latest Report on Chemed
Chemed Trading Down 1.5 %
NYSE:CHE traded down $8.69 on Thursday, hitting $554.31. 133,789 shares of the company's stock traded hands, compared to its average volume of 94,233. Chemed Co. has a 1 year low of $512.12 and a 1 year high of $654.62. The firm has a 50-day moving average price of $543.62 and a 200-day moving average price of $564.38. The company has a market cap of $8.34 billion, a PE ratio of 28.01, a price-to-earnings-growth ratio of 2.19 and a beta of 0.48.
Chemed Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, December 6th. Shareholders of record on Monday, November 18th were paid a dividend of $0.50 per share. The ex-dividend date was Monday, November 18th. This represents a $2.00 annualized dividend and a yield of 0.36%. Chemed's dividend payout ratio (DPR) is presently 10.11%.
Insider Buying and Selling at Chemed
In other Chemed news, EVP Spencer S. Lee sold 732 shares of Chemed stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $575.62, for a total transaction of $421,353.84. Following the transaction, the executive vice president now owns 18,287 shares of the company's stock, valued at $10,526,362.94. The trade was a 3.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $572.77, for a total value of $1,145,540.00. Following the transaction, the chief executive officer now directly owns 101,735 shares in the company, valued at approximately $58,270,755.95. This trade represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.32% of the company's stock.
Chemed Company Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
